BG63629B1 - Кристална форма iii на хемикалциева сол на [r-(r,r)]-2-(4-флуорофенил)-бета,делта-дихидрокси-5-(1-метил eтил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина (аторвастатин) - Google Patents

Кристална форма iii на хемикалциева сол на [r-(r*,r*)]-2-(4-флуорофенил)-бета,делта-дихидрокси-5-(1-метил eтил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина (аторвастатин) Download PDF

Info

Publication number: BG63629B1
Authority: BG; Bulgaria
Prior art keywords: atorvastatin; crystalline form; form iii; atorvastatin hydrate; fluorophenyl
Prior art date: 1995-07-17

Application number

BG102186A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102186A (en

Inventor

Ann MCKENZIE

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-17

Filing date

1998-01-14

Publication date

2002-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63629(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-01-14 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

1998-10-30 Publication of BG102186A publication Critical patent/BG102186A/xx

2002-07-31 Publication of BG63629B1 publication Critical patent/BG63629B1/bg

Links

XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims description 60
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims description 60
229960005370 atorvastatin Drugs 0.000 title claims description 60
150000003839 salts Chemical class 0.000 title abstract description 8
239000002253 acid Substances 0.000 title abstract description 3
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title abstract 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title abstract 2
239000000126 substance Substances 0.000 claims description 12
238000000634 powder X-ray diffraction Methods 0.000 claims description 10
238000005481 NMR spectroscopy Methods 0.000 claims description 9
230000005855 radiation Effects 0.000 claims description 7
239000007787 solid Substances 0.000 abstract description 9
239000000843 powder Substances 0.000 abstract description 7
201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
150000001875 compounds Chemical class 0.000 description 13
238000000034 method Methods 0.000 description 13
239000000203 mixture Substances 0.000 description 13
239000004480 active ingredient Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 10
239000002775 capsule Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000003826 tablet Substances 0.000 description 10
238000002360 preparation method Methods 0.000 description 9
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
239000002552 dosage form Substances 0.000 description 7
159000000007 calcium salts Chemical class 0.000 description 6
-1 (1-methylethyl) - Chemical class 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000006073 displacement reaction Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003529 anticholesteremic agent Substances 0.000 description 3
239000003524 antilipemic agent Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
230000000055 hyoplipidemic effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
239000001639 calcium acetate Substances 0.000 description 2
229960005147 calcium acetate Drugs 0.000 description 2
235000011092 calcium acetate Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000007940 sugar coated tablet Substances 0.000 description 2
238000009495 sugar coating Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102400001190 Vastatin Human genes 0.000 description 1
101800000422 Vastatin Proteins 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000005388 cross polarization Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
UOENAPUPIPQFOY-UHFFFAOYSA-J dicalcium tetraacetate hydrate Chemical compound O.C(C)(=O)[O-].[Ca+2].[Ca+2].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-] UOENAPUPIPQFOY-UHFFFAOYSA-J 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
150000004686 pentahydrates Chemical class 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000010453 quartz Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
BOJSDHZZKKYWAS-UHFFFAOYSA-N tetrakis(trimethylsilyl)silane Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)([Si](C)(C)C)[Si](C)(C)C BOJSDHZZKKYWAS-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG102186A 1995-07-17 1998-01-14 Кристална форма iii на хемикалциева сол на [r-(r*,r*)]-2-(4-флуорофенил)-бета,делта-дихидрокси-5-(1-метил eтил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина (аторвастатин) BG63629B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US145495P	1995-07-17	1995-07-17
PCT/US1996/011367 WO1997003958A1 (fr)	1995-07-17	1996-07-08	Forme cristalline iii d'hemi-sel de calcium d'acide [r-(r,r)]-2(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)

Publications (2)

Publication Number	Publication Date
BG102186A BG102186A (en)	1998-10-30
BG63629B1 true BG63629B1 (bg)	2002-07-31

Family

ID=21696105

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102186A BG63629B1 (bg)	1995-07-17	1998-01-14	Кристална форма iii на хемикалциева сол на [r-(r,r)]-2-(4-флуорофенил)-бета,делта-дихидрокси-5-(1-метил eтил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина (аторвастатин)

Country Status (32)

Country	Link
US (1)	US6121461A (fr)
JP (1)	JP3296563B2 (fr)
KR (1)	KR100431039B1 (fr)
CN (1)	CN1081632C (fr)
AT (1)	ATE207465T1 (fr)
AU (1)	AU725368B2 (fr)
BG (1)	BG63629B1 (fr)
BR (1)	BR9610567A (fr)
CA (1)	CA2220458C (fr)
CO (1)	CO4700442A1 (fr)
CZ (1)	CZ294109B6 (fr)
DK (1)	DK0848704T3 (fr)
EA (1)	EA000505B1 (fr)
EE (1)	EE03607B1 (fr)
ES (1)	ES2166456T3 (fr)
GE (1)	GEP20002028B (fr)
HR (1)	HRP960313B1 (fr)
HU (1)	HU223598B1 (fr)
ID (1)	ID16158A (fr)
IL (3)	IL122162A (fr)
MX (1)	MX9708857A (fr)
MY (1)	MY118398A (fr)
NO (1)	NO309899B1 (fr)
NZ (1)	NZ312906A (fr)
PE (1)	PE1798A1 (fr)
PL (1)	PL192244B1 (fr)
RO (1)	RO120068B1 (fr)
SK (1)	SK284201B6 (fr)
TW (1)	TW401399B (fr)
UA (1)	UA44796C2 (fr)
WO (1)	WO1997003958A1 (fr)
ZA (1)	ZA966045B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
KR100431038B1 (ko)	1995-07-17	2004-05-12	워너-램버트 캄파니 엘엘씨	결정질[ｒ-(ｒ,ｒ)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
IN191236B (fr)	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
CZ20021642A3 (cs) *	1999-11-17	2003-05-14	Teva Pharmaceutical Industries Ltd.	Polymorfní formy atorvastatinu vápenatého
SI20425A (sl)	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
EP1237865B1 (fr)	1999-12-17	2005-11-16	Pfizer Science and Technology Ireland Limited	Procede de production a l'echelle industrielle de sel d'hemi-calcium trihydrate d'atorvastatine cristallise
WO2001044181A1 (fr)	1999-12-17	2001-06-21	Warner Lambert Research And Development Ireland Limited	Procede pour produire de l'atorvastatine calcique cristallin
CZ20031495A3 (cs) *	2000-11-03	2004-01-14	Teva Pharmaceutical Industries Ltd.	Forma VII hemi-kalcium atorvastatinu
LT5196B (lt)	2000-11-30	2005-02-25	Teva Pharmaceutical Industries Ltd.	Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai
RU2344127C2 (ru) *	2000-11-30	2009-01-20	Тева Фамэситикл Индастрис Лтд.	Новые кристаллические структуры (полиморфные модификации) полукальциевой соли аторвастатина и способы получения этих и других полиморфных модификаций соли аторвастатина
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) *	2000-12-27	2007-04-05	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
EP1728785A1 (fr)	2001-01-09	2006-12-06	Warner-Lambert Company LLC	7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
US6476235B2 (en)	2001-01-09	2002-11-05	Warner-Lambert Company	Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (fr)	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl) *	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
SK16002003A3 (sk)	2001-06-29	2004-12-01	Warner-Lambert Company Llc	Kryštalické formy vápenatej soli (2:1) [R-(R,R)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
RU2304139C2 (ru) *	2001-07-30	2007-08-10	Д-р Редди'с Лабораторис Лтд	Кристаллические формы vi и vii кальциевой соли аторвастатина
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
DE60226044T2 (de) *	2001-08-03	2009-05-14	Ciba Holding Inc.	Kristalline formen von fluvastatin-natrium
US20060020137A1 (en) *	2001-11-29	2006-01-26	Limor Tessler	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) *	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs)	2002-02-01	2006-08-16	Zentiva, A.S.	Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
MXPA04007939A (es) *	2002-02-15	2004-11-26	Teva Pharma	Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix.
MXPA04007995A (es) *	2002-02-19	2004-11-26	Teva Pharma	Desolvatacion de solvatos de hemicalcio de atorvastatina.
RU2309141C2 (ru) *	2002-03-18	2007-10-27	Байокон Лимитид	АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
HUP0500074A3 (en) *	2002-03-18	2005-07-28	Biocon Ltd Bangalore	Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
ITMI20020907A1 (it) *	2002-04-29	2003-10-29	Chemi Spa	Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2004014896A1 (fr) *	2002-08-06	2004-02-19	Warner-Lambert Company Llc	Procede de preparation de phenylamide d'acide carboxylique 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3
US20060122403A1 (en) *	2002-09-03	2006-06-08	Sanjay Suri	Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl)	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HRP20020885B1 (en) *	2002-11-11	2007-05-31	GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o.	SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
EP1572643A2 (fr) *	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Forme cristalline du sel hemi calcique de l'atorvastatine
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
JP2006523670A (ja) *	2003-04-14	2006-10-19	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	５−（４−フルオロフェニル）−１−［２−（（２ｒ，４ｒ）−４−ヒドロキシ−６−オキソ−テトラヒドロ−ピラン−２−イル）エチル］−２−イソプロピル−４−フェニル−１ｈ−ピロール−３−カルボン酸フェニルアミドの調製方法
US7790197B2 (en) *	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) *	2003-06-12	2004-12-16	Luner Paul E.	Pharmaceutical compositions of atorvastatin
US7655692B2 (en) *	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
RU2315755C2 (ru) *	2003-09-17	2008-01-27	Уорнер-Ламберт Компани Ллс	Кристаллические формы [r-(r,r)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты
CA2562844A1 (fr) *	2004-04-16	2005-10-27	Pfizer Products Inc.	Procede pour former de l'atorvastatine calcique amorphe
US7875731B2 (en) *	2004-05-05	2011-01-25	Pfizer Inc.	Salt forms of [R-(R,R)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
AU2005263550C1 (en) *	2004-07-16	2013-01-17	Lek Pharmaceuticals D.D.	Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) *	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
CA2578722C (fr)	2004-08-27	2010-02-02	Biocon Limited	Processus pour calcium d'atorvastatine amorphe
US7674923B2 (en) *	2004-09-28	2010-03-09	Teva Pharmaceutical Industries Ltd	Process for preparing forms of atorvastatin calcium substantially free of impurities
KR20070054730A (ko)	2004-10-18	2007-05-29	테바 파마슈티컬 인더스트리즈 리미티드	알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
CA2585836A1 (fr)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Procede de formation d'atorvastatine amorphe
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
WO2006054308A2 (fr)	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Formulations d'atorvastatine stables
CA2589537A1 (fr) *	2004-12-02	2006-06-08	Stephen Craig Dyar	Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
GB2424880A (en) *	2005-04-06	2006-10-11	Generics	Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
CA2547216A1 (fr) *	2005-09-21	2007-03-21	Renuka D. Reddy	Procede de recuit de l'atorvastatine amorphe
WO2007057755A1 (fr)	2005-11-21	2007-05-24	Warner-Lambert Company Llc	Nouvelles formes d’acide [r-(r,r)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique magnesium
CA2633268A1 (fr)	2005-12-13	2007-06-21	Teva Pharmaceutical Industries Ltd.	Forme cristalline d'hemi-calcium d'atorvastatine et procedes de fabrication de celle-ci
EP1810667A1 (fr)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique contenant de l'atorvastatin amorphé
CA2640573A1 (fr) *	2006-03-01	2007-09-13	Michael Pinchasov	Procede de preparation d'une forme cristalline d'hemi-calcium d'atorvastatine
US20070265456A1 (en) *	2006-05-09	2007-11-15	Judith Aronhime	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100878140B1 (ko) *	2007-01-29	2009-01-12	한미약품 주식회사	아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
WO2009007856A2 (fr) *	2007-07-11	2009-01-15	Actavis Group Ptc Ehf	Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
WO2009013633A2 (fr) *	2007-07-20	2009-01-29	Actavis Group Ptc Ehf	Coprécipités amorphes de sels pharmaceutiquement acceptables d'atorvastatine
DE102007052071A1 (de)	2007-10-30	2009-05-07	Stada Arzneimittel Ag	Stabilisiertes Atorvastatin
US20090124817A1 (en) *	2007-11-09	2009-05-14	The Industry & Academic Cooperation In Chungnam National University	Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
US8115015B2 (en) *	2009-01-26	2012-02-14	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs)	2010-01-19	2011-07-27	Zentiva, K. S	Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN102424663B (zh) *	2010-12-03	2013-08-14	天津滨江药物研发有限公司	一种阿托伐他汀氨基酸盐及其制备方法
US9050342B2 (en)	2011-03-29	2015-06-09	Pfizer Inc.	Beneficial effects of combination therapy on cholesterol
US20140335179A1 (en) *	2011-07-01	2014-11-13	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Micronized crystals of atorvastatin hemicalcium
CN103483238B (zh) *	2013-08-20	2014-12-31	蚌埠丰原医药科技发展有限公司	阿托伐他汀钙三水合物的制备方法
CN106432033B (zh) *	2016-10-21	2018-07-27	江苏阿尔法药业有限公司	一种无定形阿托伐他汀钙的制备方法
KR101723783B1 (ko)	2017-02-24	2017-04-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE409281C (de) *	1922-04-26	1925-01-31	Farbenfab Vorm Bayer F & Co	Verfahren zur Herstellung von sauren Monoazofarbstoffen fuer Wolle
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) *	1989-09-07	1994-05-31	Karl Folkers Foundation For Biomedical And Clinical Research	Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
JP3254219B2 (ja) *	1993-01-19	2002-02-04	ワーナー−ランバート・コンパニー	安定な経口用のｃｉ−９８１製剤およびその製法

1996
- 1996-07-03 HR HR960313A patent/HRP960313B1/xx not_active IP Right Cessation
- 1996-07-08 CN CN96195632A patent/CN1081632C/zh not_active Expired - Lifetime
- 1996-07-08 GE GEAP19964148A patent/GEP20002028B/en unknown
- 1996-07-08 WO PCT/US1996/011367 patent/WO1997003958A1/fr not_active Ceased
- 1996-07-08 JP JP50670997A patent/JP3296563B2/ja not_active Expired - Lifetime
- 1996-07-08 CA CA002220458A patent/CA2220458C/fr not_active Expired - Lifetime
- 1996-07-08 AT AT96924367T patent/ATE207465T1/de not_active IP Right Cessation
- 1996-07-08 MX MX9708857A patent/MX9708857A/es active IP Right Grant
- 1996-07-08 CZ CZ1998123A patent/CZ294109B6/cs not_active IP Right Cessation
- 1996-07-08 PL PL324532A patent/PL192244B1/pl unknown
- 1996-07-08 BR BR9610567A patent/BR9610567A/pt not_active Application Discontinuation
- 1996-07-08 DK DK96924367T patent/DK0848704T3/da active
- 1996-07-08 EE EE9800016A patent/EE03607B1/xx unknown
- 1996-07-08 AU AU64841/96A patent/AU725368B2/en not_active Expired
- 1996-07-08 NZ NZ312906A patent/NZ312906A/xx not_active IP Right Cessation
- 1996-07-08 RO RO98-00059A patent/RO120068B1/ro unknown
- 1996-07-08 SK SK59-98A patent/SK284201B6/sk not_active IP Right Cessation
- 1996-07-08 IL IL12216296A patent/IL122162A/xx not_active IP Right Cessation
- 1996-07-08 HU HU9901687A patent/HU223598B1/hu active IP Right Grant
- 1996-07-08 EA EA199800129A patent/EA000505B1/ru not_active IP Right Cessation
- 1996-07-08 ES ES96924367T patent/ES2166456T3/es not_active Expired - Lifetime
- 1996-07-08 KR KR10-1998-0700347A patent/KR100431039B1/ko not_active Expired - Lifetime
- 1996-07-10 TW TW085108326A patent/TW401399B/zh not_active IP Right Cessation
- 1996-07-11 IL IL128863A patent/IL128863A/en not_active IP Right Cessation
- 1996-07-15 ID IDP962021A patent/ID16158A/id unknown
- 1996-07-16 ZA ZA9606045A patent/ZA966045B/xx unknown
- 1996-07-16 MY MYPI96002920A patent/MY118398A/en unknown
- 1996-07-17 CO CO96037513A patent/CO4700442A1/es unknown
- 1996-07-17 PE PE1996000540A patent/PE1798A1/es not_active Application Discontinuation
- 1996-08-07 UA UA98020825A patent/UA44796C2/uk unknown
1998
- 1998-01-14 BG BG102186A patent/BG63629B1/bg unknown
- 1998-01-16 NO NO980208A patent/NO309899B1/no not_active IP Right Cessation
1999
- 1999-07-26 US US09/360,778 patent/US6121461A/en not_active Expired - Lifetime
2006
- 2006-08-08 IL IL177378A patent/IL177378A0/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP9901687A2 (hu)	1999-10-28
EE03607B1 (et)	2002-02-15
HRP960313B1 (en)	2002-08-31
NO980208L (no)	1998-01-16
CN1190957A (zh)	1998-08-19
WO1997003958A1 (fr)	1997-02-06
CZ12398A3 (cs)	1998-06-17
CA2220458A1 (fr)	1997-02-06
MY118398A (en)	2004-10-30
PE1798A1 (es)	1998-03-04
NZ312906A (en)	2000-12-22
EA199800129A1 (ru)	1998-08-27
SK5998A3 (en)	1998-05-06
MX9708857A (es)	1998-03-31
IL122162A0 (en)	1998-04-05
SK284201B6 (sk)	2004-10-05
HK1018053A1 (en)	1999-12-10
ID16158A (id)	1997-09-11
ZA966045B (en)	1997-02-04
US6121461A (en)	2000-09-19
KR19990029044A (ko)	1999-04-15
ATE207465T1 (de)	2001-11-15
RO120068B1 (ro)	2005-08-30
AU725368B2 (en)	2000-10-12
UA44796C2 (uk)	2002-03-15
ES2166456T3 (es)	2002-04-16
TW401399B (en)	2000-08-11
AU6484196A (en)	1997-02-18
HU223598B1 (hu)	2004-10-28
IL177378A0 (en)	2006-12-10
PL192244B1 (pl)	2006-09-29
CA2220458C (fr)	2002-09-24
DK0848704T3 (da)	2002-02-04
GEP20002028B (en)	2000-04-10
CO4700442A1 (es)	1998-12-29
CN1081632C (zh)	2002-03-27
JP3296563B2 (ja)	2002-07-02
EA000505B1 (ru)	1999-10-28
NO309899B1 (no)	2001-04-17
PL324532A1 (en)	1998-06-08
CZ294109B6 (cs)	2004-10-13
HRP960313A2 (en)	1998-04-30
BG102186A (en)	1998-10-30
EE9800016A (et)	1998-08-17
IL128863A (en)	2006-09-05
NO980208D0 (no)	1998-01-16
HUP9901687A3 (en)	2000-04-28
KR100431039B1 (ko)	2004-08-25
IL122162A (en)	1999-07-14
JPH11509229A (ja)	1999-08-17
BR9610567A (pt)	1999-07-06
IL128863A0 (en)	2000-01-31

Publication	Publication Date	Title
JP3296563B2 (ja)	2002-07-02	形態▲ＩＩＩ▼の結晶性の（Ｒ−（Ｒ▲上＊▼，Ｒ▲上＊▼））−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチル−エチル）−３−フェニル−４−（（フェニルアミノ）カルボニル）−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）
EP1148049B1 (fr)	2004-12-15	Formes cristallines d'hémi-sel de calcium d'acide r-(r,r)]-2-(4-fluorophényl)-beta,delta-dihydroxy-5-(1-methyléthyl)-3-phényl-4- (phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)
JP2003073353A6 (ja)	2006-10-26	結晶性の〔Ｒ−（Ｒ＊，Ｒ＊）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）
MXPA97009099A (en)	1998-02-01	Salt hemi calcium of acid [r- (r , r ,)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylthyl) -3-phenyl-4 - [(phenylamine) carbonil] -1h-pirrole-1-heptanoico (atorvastat
BG63631B1 (bg)	2002-07-31	Нов метод за получаване на аморфна калциева сол на [r-(r,r)]-2-(4-флуорофенил)-бета,делта-дихидрокси- 5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н- пирол-1-хептанова киселина (2:1)
EP0848704B1 (fr)	2001-10-24	Forme cristalline iii d'hemi-sel de calcium d'acide [r-(r,r)]-2(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)
JP2003073354A6 (ja)	2006-10-26	形態ＩＩＩの結晶性の（Ｒ−（Ｒ＊，Ｒ＊））−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチル−エチル）−３−フェニル−４−（（フェニルアミノ）カルボニル）−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）
JP2003073354A (ja)	2003-03-12	形態ＩＩＩの結晶性の（Ｒ−（Ｒ＊，Ｒ＊））−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチル−エチル）−３−フェニル−４−（（フェニルアミノ）カルボニル）−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）